Cancer therapeutics: Time to swim downstream?

Oncologist

Volumn 16, Issue 10, 2011, Pages 1479-1480

  Steinman, Richard ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHEMOKINE; CYTOKINE; FIBROBLAST ACTIVATION PROTEIN; GAMMA SECRETASE; GENE PRODUCT; INTERLEUKIN 6; RANTES; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; CANCER CELL; DRUG TARGETING; FLUORESCENCE IMAGING; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; STROMA; TUMOR MICROENVIRONMENT; TUMOR STROMA;

BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; FEMALE; FIBROBLASTS; HUMANS; STROMAL CELLS;

EID: 80054796499     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0241     Document Type: Article

References (5)

1. Migneco G, Whitaker-Menezes D, Chiavarina B et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010;9:2412-2422.
2. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: A novel tumorpromoting cell type. Cell Cycle 2006;5:1597-1601.
3. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: Complex tissues that interface with the entire organism. Dev Cell 2010;18:884-901.
4. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-252.
5. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008;57:1-17.